OncoMatch/Clinical Trials/NCT06554626
Blinatumomab Plus Venetoclax Sequenced With Inotuzumab Ozogamicin in Treating B-ALL
Is NCT06554626 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies multiple treatments for precursor b-cell lymphoblastic leukemia.
Treatment: Dexamethasone · Blinatumomab · Venetoclax · Inotuzumab ozogamicin · Methotrexate · Pegaspargase · Cytarabine — Precursor B cell acute lymphoblastic leukemia (B-ALL) is an aggressive type of leukemia, with high relapse rate and poor long term survival in adults. Traditional treatment regimens mainly include chemotherapy and hematopoietic stem cell transplantation. In the past decade, with the application of molecular targeted drugs and immunotherapy, the survival of B-ALL patients has significantly improved. In this study，we propose a treatment approach that combines Blinatumomab and Venetoclax sequenced with Inotuzumab Ozogamicin in B-ALL adults. Our study aims to answer the safety and efficacy of this treatment regimen, and further improve the survival for those participants.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Immunotherapy
Targeted therapy
Chemotherapy
Other
Cancer type
Acute Lymphoblastic Leukemia
Biomarker criteria
Required: ABL1 wild-type
Required: BCR wild-type
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Demographics
Prior therapy
Lab requirements
Kidney function
serum creatinine ≤ 1.5 ULN
Liver function
Serum total bilirubin ≤ 1.5 ULN; ALT or AST ≤ 2.5 ULN
Cardiac function
LVEF ≥ 45%
Serum total bilirubin > 1.5 ULN (upper limit of normal); ALT or AST > 2.5 ULN; serum creatinine > 1.5 ULN; Cardiac ultrasound LVEF < 45%
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06554626 currently recruiting?
Yes, this trial is currently recruiting patients.
Can patients have received prior systemic therapy?
No. This trial requires treatment-naive patients — prior systemic therapy is an exclusion criterion.
Does this trial require ABL1?
Yes, ABL1 wild-type is a required biomarker for enrollment.
Does this trial require BCR?
Yes, BCR wild-type is a required biomarker for enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages